{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:23:52Z","timestamp":1793618632116,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Copenhagen University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Capital Region of Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.atherosclerosis.2024.117556","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T05:32:29Z","timestamp":1713591149000},"page":"117556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial"],"prefix":"10.1016","volume":"393","author":[{"given":"Takahito","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.117556_bib1","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib3","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.5551\/jat.RV22013","article-title":"Lipoproteins, cholesterol, and atherosclerotic cardiovascular disease in East Asians and Europeans","volume":"30","author":"Doi","year":"2023","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib10","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib12","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib13","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/joim.13771","article-title":"Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials","volume":"295","author":"Doi","year":"2024","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib15","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib16","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.05.010","article-title":"Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality","volume":"379","author":"Doi","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.22384","article-title":"Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population","volume":"69","author":"Varbo","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012817","article-title":"Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study","volume":"6","author":"Adelborg","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib21","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgz265","article-title":"Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides","volume":"105","author":"Langsted","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MED.0000000000000799","article-title":"Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease?","volume":"30","author":"Doi","year":"2023","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib27","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bjornson","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib28","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1093\/eurheartj\/ehad419","article-title":"Triglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important?","volume":"44","author":"Tybjaerg-Hansen","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPARalpha modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI108229","article-title":"Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects","volume":"56","author":"Sigurdsson","year":"1975","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2760(96)00066-5","article-title":"The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation","volume":"1302","author":"Schoonjans","year":"1996","journal-title":"Biochim. Biophys. Acta Lipids Lipid. Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","article-title":"Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia","volume":"261","author":"Arai","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib36","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2337\/dc21-1288","article-title":"Efficacy and safety of K-877 (pemafibrate), a selective PPARalpha modulator, in European patients on statin therapy","volume":"45","author":"Ginsberg","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib37","unstructured":"Pharmaceuticals and Medical Devices Agency of Japan, Review report of Parmodia Tab. 0.1 mg. Section 6.2.6. Accessed October 27, 2022. https:\/\/www.pmda.go.jp\/files\/000226672.pdf."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosissup.2018.04.474","article-title":"Pemafibrate minimally affected the systemic exposure of statins, and vice versa, in healthy male volunteers","volume":"32","author":"Hounslow","year":"2018","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib41","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117556_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T21:19:33Z","timestamp":1717190373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":42,"alternative-id":["S0021915024001163"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117556","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117556"}}